Effects of the Selective Serotonin Reuptake Inhibitor Fluoxetine on Counterregulatory Responses to Hypoglycemia in Individuals With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans. However, virtually no information exists regarding the effects of fluoxetine on integrated physiological counterregulatory responses during hypoglycemia in type 1 diabetes. Therefore, the specific aim of this study was to test the hypothesis that 6-week use of the SSRI fluoxetine would amplify autonomic nervous system (ANS) counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS—Eighteen type 1 diabetic patients (14 men/4 women aged 19–48 years with BMI 25 ± 3 kg/m2 and A1C 7.0 ± 0.4%) participated in randomized, double-blind 2-h hyperinsulinemic (9 pmol · kg−1 · min−1)-hypoglycemic clamp studies before and after 6 weeks of fluoxetine administration (n = 8) or identical placebo (n = 10). Glucose kinetics was determined by 3-tritiated glucose. Muscle sympathetic nerve activity (MSNA) was determined by microneurography. RESULTS—Hypoglycemia (2.8 ± 0.1 mmol/l) and insulinemia (646 ± 52 pmol/l) were similar during all clamp studies. ANS, neuroendocrine, and metabolic counterregulatory responses remained unchanged in the placebo group. However, fluoxetine administration significantly (P < 0.05) increased key ANS (epinephrine, norepinephrine, and MSNA), metabolic (endogenous glucose production and lipolysis), and cardiovascular (systolic blood pressure) counterregulatory responses during hypoglycemia. CONCLUSIONS—This study has demonstrated that 6-week administration of the SSRI fluoxetine can amplify ANS and metabolic counterregulatory mechanisms during moderate hypoglycemia in patients with type 1 diabetes. These data also suggest that the use of fluoxetine may be useful in increasing epinephrine responses during hypoglycemia in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115 · cited 11×
“Two recent studies have also demonstrated that chronic administration of different SSRIs can amplify counterregulatory responses during hypoglycemia in both healthy humans and conscious rats (9,10).”
BackgroundInfluentialGerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
Plasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man
WALLIN, B. G., SUNDLÖF, G., ERIKSSON, B., DOMINIAK, P., GROBECKER, H., & LINDBLAD, L. E. (1981) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1981.tb06706.x · Cited by 316
Amiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis
Deary, I. J., Hepburn, D. A., MacLeod, K. M., & Frier, B. M. (1993) · Diabetologia · doi:10.1007/bf00401150 · Cited by 286
Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia
Teves, D., Videen, T. O., Cryer, P. E., & Powers, W. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307048101 · Cited by 138 · cited 1×
“Recent work in humans has demonstrated that hippocampal and thalamic regions of the brain are activated during hypoglycemia (35).”
BackgroundDifferential effects of epinephrine on glucose production and disposal in man.
Rizza, R., Haymond, M., Cryer, P., & Gerich, J. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.4.e356 · Cited by 115 · cited 1×
“Previous studies have demonstrated that the doseresponse effects of epinephrine to inhibit glucose uptake are relatively flat (33,34) in association with increasing the concentrations of the catecholamines from 600 to 1,000 pg/ml, producing limited actions.”
BackgroundDavis, S. N., Shavers, C., & Costa, F. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e1054 · Cited by 86 · cited 1×
“The subjects were stratified according to sex because it is known to affect the counterregulatory response (16).”
BackgroundSelf-citationDiffering physiological effects of epinephrine in type 1 diabetes and nondiabetic humans
Guy, D. A., Sandoval, D., Richardson, M. A., Tate, D., Flakoll, P. J., & Davis, S. N. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00310.2004 · Cited by 21
Self-citation
Cited by
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Gogitidze Joy, N., Hedrington, M. S., Briscoe, V. J., Tate, D. B., Ertl, A. C., & Davis, S. N. (2010) · Diabetes Care · doi:10.2337/dc09-0354 · Cited by 239
Self-citation(2011) · PubMed · Cited by 187
Rickels, M. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14214 · Cited by 71
The physiology and pathophysiology of the neural control of the counterregulatory response
Beall, C., Ashford, M. L., & McCrimmon, R. J. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00531.2011 · Cited by 63
Metadata
- Authors
- Briscoe, V. J., Ertl, A. C., Tate, D. B., & Davis, S. N.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-12-01
- Volume
- 57
- Issue
- 12
- Pages
- 3315-3322
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2161776649
- Cited by
- 47
- References
- 10
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.